

3rd International Conference on **Nephrology & Therapeutics**

June 26-27, 2014 Valencia Conference Centre, Valencia, Spain

Uric acid and its role in kidney disease

Raj P Singh

Kidney Specialists of Southern Nevada, USA

Hyperuricemia is common in patients with chronic kidney disease. Despite recent studies showing a potential benefit of uric acid lowering therapy in delaying the progression of chronic kidney disease, its role in the treatment of patients with chronic kidney disease remains controversial. Unlike acute uric acid nephropathy (urate nephropathy), the mechanism of renal injury from chronic asymptomatic hyperuricemia is poorly understood. Animal data has shown that hyperuricemia is associated with glomerular hypertension and interstitial fibrosis. However, human studies have not definitively shown clinical benefit. Uric acid lowering agents can also have significant side effects in patients with chronic kidney disease due to impaired renal clearance. Based on the current body of evidence, the use of uric acid lowering therapy to delay the progression of chronic kidney disease is not indicated.

Biography

Raj P Singh received his MD internal medicine degree from University of Nevada School of Medicine in Las Vegas and completed his fellowship in Nephrology and Hypertension from University of Kansas. He is a Nephrologist in private practice, faculty at University of Nevada School of medicine and is actively involved in teaching of medicine students, residents, trauma critical care fellows. He is the founding member of healthtap.com and also a leading nephrology expert on allexperts.com. He has received several awards such as Vegas Top Doc award, Top Nephrologist Nevada. He is co-chairman of pharmacy and therapeutics committee at University Medical Center and has presented several abstracts/research posters at American College of Physicians annual regional conference.

rsingh@ksosn.com